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ABSTRACT 28 
Background and aims: CD36 is a cholesterol receptor involved in the uptake of oxidized 29 
low-density lipoprotein cholesterol and development of atherosclerotic plaques. 30 
Cross-sectional studies have shown correlations between plasma CD36 and atherosclerosis 31 
but no prospective study has examined the associatin yet. We prospectively examined the 32 
association between plasma CD36 levels and risk of incident coronary heart disease (CHD) in 33 
a Danish population. 34 
Methods: Plasma CD36 levels were measured in a case-cohort study nested within the Danish 35 
population-based cohort, the Diet, Cancer and Health Study. A total of 1,963 incident CHD 36 
events occurred between baseline (1993-1997) and 2008, and a sub-cohort of 1,759 37 
participants were randomly selected as reference. Cox proportional hazard regression models 38 
were used to compute the hazard ratio (HR) and corresponding 95% confidence interval (CI). 39 
Results: After adjusting for CHD risk factors, including history of hypercholesterolemia and 40 
diabetes, elevated plasma CD36 levels were not associ ted with higher CHD risk in the total 41 
population, and the HR comparing the highest versus lowest tertile of CD36 levels was 1.02 42 
(95% CI 0.84-1.23). High CD36 levels were only found to be associated with risk of CHD in 43 
combination with prevalent diabetes (HR=2.83, 95% CI: 1.08-7.45) vs. the joint reference 44 
group of lowest CD36 tertile and no diabetes.  45 
Conclusions: Plasma CD36 levels were not predictive of CHD riskin the general population.   46 
Keywords: case-cohort study, coronary heart disease, plasma CD36, prospective study 47 
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INTRODUCTION 48 
Coronary heart disease (CHD) arising from atherosclerosis is a leading cause of death 49 
and morbidity worldwide [1]. Atherosclerosis is considered a chronic inflammatory disease 50 
consists of plaque initiation, progression and thromb sis [2]. The transmembrane 51 
glycoprotein CD36 is an important multi-ligand class B scavenger receptor in monocytes and 52 
macrophages that internalizes oxidized low-density lipoprotein (ox-LDL) cholesterol in the 53 
subendothelial spaces of arteries and subsequently differentiates the macrophages into foam 54 
cells, which is the hallmark of early atherosclerotic lesions [3, 4]. In addition, CD36 is also a 55 
fatty acid transporter in metabolically active tissue  (muscle, liver and adipocytes) that is 56 
implicated in the development of insulin resistance [5-7], which is another important risk 57 
factor for developing atherosclerosis [8]. The importance of CD36 in the pathogenesis of 58 
atherosclerosis has been shown in animal studies whre double apoE/CD36 knockout mice 59 
who develop significantly smaller atherosclerotic lesions compared to the wild-type controls 60 
[9], have a doubling in lesion area when CD36 is reint oduced [10]. In addition, several 61 
human genome-wide linkage studies have shown that the location of the CD36 gene locus on 62 
chromosome 7q is associated with myocardial infarction and stroke [11]. In addition, in 63 
comparison to individials with asyumptomatic carotid plaques, CD36 gene expression has 64 
been found to be up-regulated in patients with sympto atic carotid plaques [12]. This 65 
suggests that CD36 could be a useful biomarker in the early development of cardiovascular 66 
disease. 67 
The expression of CD36 is increased in macrophages, smooth muscle cells, and 68 
endothelial cells in atherosclerosis plaques [13]. However, previous studies of membrane 69 
CD36 in monocytes and macrophages require fresh blood samples for measurement [14-17], 70 
and thus were not well suited for large population-based epidemiological studies. To tackle 71 
this issue, Handberg et al. [18] developed an assay to nalyze the stored plasma samples, and 72 
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identified a circulating form of CD36 in human plasma. Plasma CD36 was hypothesized to 73 
be released into the circulation as part of the low-grade inflammatory state in insulin 74 
resistance and atherosclerosis [18], and the levels have been found to be moderately 75 
correlated with membrane CD36 expression in liver tissue [19]. While two cross-sectional 76 
studies have reported correlations between plasma CD36 and carotid atherosclerosis among 77 
both healthy populations and patients with high-grade internal carotid stenosis [20, 21], one 78 
study did not find such correlation among patients wi h early coronary artery disease [22]. 79 
Thus far, no prospective studies have been conducte to valuate the association between 80 
plasma CD36 and risk of CHD. 81 
Therefore, we conducted a case-cohort study in a large population-based cohort 82 
among Danish men and women to examine the association between plasma CD36 and risk of 83 
CHD. We also investigated whether this association is modified by important cardiovascular 84 
risk factors including obesity, smoking status, as well as history of hypercholesterolemia and 85 
diabetes. 86 
 87 
MATERIALS AND METHODS 88 
Study population 89 
The Danish Diet, Cancer and Health study is an ongoing prospective study established 90 
between 1993 and 1997, and recruited 57,053 cancer-free participants aged between 50 and 91 
65 years who lived in the urban areas of Copenhagen nd Aarhus [23]. At baseline, 92 
participants filled out self-administered lifestyle questionnaires, and the questions included 93 
self-reported type 2 diabetes and hypercholesterolemia. In addition, technicians obtained 94 
anthropometric measurements and collected non-fasting blood samples at the study clinic. 95 
Blood specimens were separated into plasma, serum, lymphocytes, and erythrocytes and 96 
frozen at −150◦ C within two hours of collection. The detailed design of the study has 97 
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described previously [23]. The study protocol complied with the Helsinki declaration and was 98 
approved by the National Committee on Health Research Ethics and the Danish Data 99 
Protection Agency (KF 01-116/96). Informed consent was completed and obtained from all 100 
participants at the baseline interview. 101 
CHD cases were identified via the National Diabetes R gistry using the personal 102 
identification number assigned to all Danish citizens in the Danish Civil Registration System. 103 
Cases were identified when participants registered with a first-time discharge diagnosis of 104 
myocardial infarction (International Classification f Diseases [ICD], 8th revision codes 410 105 
to 410.99; and ICD 10th revision codes I21.0-I21.9) [24, 25]. Medical records were retrieved 106 
from hospitals, reviewed in accordance with current guidelines [26], and myocardial 107 
infarctions diagnoses in the National Diabetes Registry are recorded with a high degree of 108 
validity [27]. Furthermore, we included participants with a sudden cardiac death diagnosis in 109 
the Cause of Death Register (ICD 8: 427.27 or ICD 10: I46.0-I46.9) if the cardiac arrest after 110 
validation was believed to be caused by a myocardial infarction.  111 
We investigated the association between plasma CD36 and risk of CHD (non-fatal 112 
myocardial infarction and fatal CHD) in a case-cohort study nested within the Danish Diet, 113 
Cancer and Health study. For the current analysis, all confirmed incident cases between study 114 
entry and May 2008 (n=1,977) were included along with a randomly chosen sub-cohort of 115 
participants drawn from the entire study population at baseline (n=1,824). After additional 116 
exclusion of participants with missing covariate values, the case-cohort included 1,963 117 
incident CHD cases (58 within the reference sub-cohort) and 1,701 non-cases (sub-cohort 118 
total n=1,759). 119 
Biochemical measurements 120 
For the measurement of CD36 concentrations, plasma sa ples from the baseline 121 
exam were sent to Aarhus University hospital and Handberg’s in-house ELISA assay was 122 
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used [18]. While phosphate-buffered saline was served as background, a pool of 123 
ethylenediaminetetraacetic acid (EDTA) plasma was applied in increasing dilutions and used 124 
to produce a standard concentration curve. Absorptions were calculated relative to the 125 
standard EDTA plasma pool and expressed as relative units. Internal controls consisting of an 126 
EDTA plasma pool and recombinant CD36 (generously donated by Randox, Laboratories 127 
[Antrim, United Kingdom]) were run in duplicates and in four concentrations on each plate. 128 
Analytical runs were accepted if one of the internal controls was within mean ± 1 standard 129 
deviation (SD) and the other control was within ± 2SD. The intra-assay coefficient of 130 
variation (CV) was 11% (plasma pool, mean 0.14 arbitrary units), and total day-to-day assay 131 
CV was 25% (plasma pool) and 19% (recombinant CD36). The relatively high CVs (≥15%) 132 
suggested the existence of moderate variability betwe n batches. To account for batch 133 
variability, we performed recalibration by regressing CD36 levels on batch and other 134 
variables associated with CD36 levels including age, sex, smoking status, alcohol intake, and 135 
education [28], that might have been unevenly distribu ed across batches by chance. 136 
Statistical methods 137 
We evaluated the baseline characteristics of participants who developed CHD during 138 
follow-up and the random sub-cohort members separately with medians and 5th/95th 139 
percentiles. The difference of plasma CD36 levels btween gender, smoking status, adiposity 140 
level, as well as history of diabetes and hypercholesterolemia were examined by two-tailed t 141 
tests in sub-cohort population with adjustment for age and sex. Plasma levels of CD36 were 142 
categorized into tertiles based on the distribution of CD36 in sub-cohort participants. Cox 143 
proportional hazard regression using age as the undrlying time-scale with standard inverse 144 
probability weights and robust variation to account for the case-cohort design was used to 145 
estimate the hazard ratio (HR) and corresponding 95% confidence interval (CI) of CHD 146 
comparing the highest versus lowest tertile of plasma CD36 levels. Person-years were 147 
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calculated from the study entry to diagnosis of CHD, death, emigration, or end of follow-up 148 
in 2008, whichever came first. Multivariable model was adjusted for potential confounders 149 
including age (continuous), sex (men, women), smoking (never; former; current <15, 15-24, 150 
≥25 grams of tobacco/day), length of school education (short < 8; medium 8-10; long >10 151 
years), BMI (continuous), alcohol intake (nondrinker; drinker, <5, 5-9, 10-19, 20-39, ≥40 152 
grams of alcohol/day), as well as self-reported hypercholesterolemia and diabetes (yes, no). 153 
In addition, we also examined the possible non-linear r lation between plasma CD36 and 154 
CHD risk using restricted cubic spline regression with 3 knots at 25th, 50th and 75th 155 
percentiles of plasma CD36 concentrations. If no deviation from linearity was detected, we 156 
also calculated the CHD risk associated with per SD increment of plasma CD36. Moreover, 157 
age- and sex-adjusted means of plasma CD36 levels were compared between subgroups of 158 
sex (men, women), smoking status (current smokers, non-smokers), history of diabetes (yes, 159 
no), body mass index (<25 kg/m2, 25-<30 kg/m2, ≥30 kg/m2) and history of 160 
hypercholesterolemia (yes, no). Furthermore, we evaluated the joint effect between t rtiles of 161 
plasma CD36 and different cardiovascular risk factors, using the lowest tertile of plasma 162 
CD36 and the low-risk category of each risk factor as the reference. This corresponds to the 163 
evaluation of biological interaction on the additive scale, as per Rothman. From these results, 164 
we can qualitatively judge whether the combined exposure to high CD36 and a risk factor, 165 
such as diabetes, is greater than expected based on the independent “effect” of each. To get a 166 
P for interaction, we used the multiplicative model where plasma CD36 was modeled 167 
continuously and included also the risk factor and interaction term between them. Data were 168 
analyzed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Two-sided p 169 
values of <0.05 were considered to be statistically significant. 170 
 171 
 172 
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RESULTS 173 
Population characteristics 174 
The characteristics of the case-cohort participants re shown in Table 1. The median 175 
age at baseline was 58 years for the participants tha  developed CHD and 55 years for the 176 
randomly selected sub-cohort individuals. In comparison to the sub-cohort participants, those 177 
who developed CHD were more likely to be male, current smokers, had higher BMI, lower 178 
education, and history of diagnosed hypercholesterolemia or diabetes. In addition, cases had 179 
higher concentrations of plasma CD36 compared with sub-cohort participants. Within the 180 
sub-cohort, the mean value of plasma CD36 levels was substantially higher among men 181 
compared to women (p=0.04; Table 2), and among obese participants compared to subjects 182 
with normal weight (p=0.02; Table 2).  183 
Associations of plasma CD36 and CHD risk 184 
After adjustment for age, sex and lifestyle factors, elevated plasma CD36 levels were 185 
not associated with higher risk of CHD; the HR comparing the highest versus lowest tertile of 186 
plasma CD36 levels was 1.02 (95% CI 0.84- 1.23; Table 3). Restricted cubic spline 187 
regression analysis did not suggest a non-linear rel tionship between plasma CD36 and CHD 188 
risk (p=0.99 for nonlinearity; Supplementary Figure 1). When modelling plasma CD36 as a 189 
continuous variable, the HR (95% CI) for CHD with per-1 SD increment in plasma CD36 190 
was 1.01 (0.93-1.07) in the multivariable model. The results were materially unchanged after 191 
further adjustment for postmenopausal status and hormone therapy. In sensitivity analyses, 192 
we repeated the analysis after trimming CD36 levels by 5th and 95th percentile, and found a 193 
similar association between plasma CD36 and CHD risk (HR per SD:1.05; 95% CI 194 
0.92-1.19). 195 
Joint analysis with cardiovascular risk factors 196 
In joint models, a higher CD36 level did not add to the risk of CHD beyond sex, 197 
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smoking, obesity, and hypercholesterolemia (T ble 4). However, elevated plasma CD36 198 
levels were associated with higher CHD-risk among people with diabetes. Compared with 199 
participants who were in the lowest plasma CD36 tertile and free of diabetes, higher CD36 200 
levels were not associated with higher CHD-risk among non-diabetic individuals (HR 201 
comparing the highest versus lowest tertile of plasma CD36 levels was 1.00 (95% CI 0.83- 202 
1.21), whereas the HR among participants was 2.83 (95% CI: 1.08, 7.45) for diabetic 203 
participants with the highest CD36 level. Nevertheless, no significant interactions were 204 
observed between CD36 with all these cardiovascular risk factors (all P-interaction >0.05).  205 
 206 
DISCUSSION 207 
In this large, prospective case-cohort study among Danish men and women, elevated 208 
plasma CD36 levels were not associated with higher CHD-risk in the overall population. 209 
However, a suggestive positive association between elevated plasma CD36 levels and higher 210 
CHD-risk was observed among participants with prevalent diabetes.  211 
Thus far, only cross-sectional studies have been conducted to explore the relationship 212 
between plasma CD36 and presence of atherosclerosis [20-22]. Among 62 Norwegian 213 
patients with high-grade internal carotid stenosis, Handberg et al. [21] found that patients 214 
with echolucent carotid plaques had higher plasma CD36 than those with 215 
echogenic/heterogeneous plaques, and suggested that CD36 may play a critical role in plaque 216 
instability and symptomatic carotid atherosclerosis. Furthermore, a study of 1029 healthy 217 
individuals from 14 European countries found a weak correlation (r=0.10; p<0.01) between 218 
plasma CD36 and carotid atherosclerosis as reflected by intima-media thickness [20]. 219 
However, in contrast, a recent study from Poland did not find any significant correlations 220 
between plasma CD36 concentrations and atherosclerois (using a comprehensive set of 221 
radiological parameters) among 70 patients with early-onset coronary artery disease [22]. 222 
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Reverse causality is a concern in these reports since the temporal relations cannot be 223 
determined from cross-sectional studies. To the best of our best knowledge, the current study 224 
is the first prospective population-based study to investigate the association between plasma 225 
CD36 and CHD-risk. During the 14-year follow-up, wedid not observe a positive association 226 
between plasma CD36 levels and CHD risk in the general population, but we found a 227 
moderate positive association among participants with self-reported diabetes. However, given 228 
the multiple statistical tests and small number of diagnosed diabetes cases, our observed 229 
association between plasma CD36 and CHD among partici nts with prevalent diabetes 230 
could also be due to chance, and should be interpret d with caution.  231 
Although the underlying mechanism is not clear yet,plasma CD36 was previously 232 
hypothesized to be released into the circulation as part of the low-grade inflammatory state in 233 
insulin resistance and atherosclerosis in a previous st dy [18]. Plasma CD36 levels 234 
moderately correlated with membrane CD36 expression in liver tissue (correlation=0.37; 235 
p=0.07) [19], and elevated plasma CD36 levels were observed in obese people and patients 236 
with type 2 diabetes, in accordance with raised tissue CD36 expression reported by others [5, 237 
15, 16, 29, 30]. 238 
Several lines of experimental evidence also suggests tha  membrane CD36 is 239 
implicated in the pathophysiology of developing insulin resistance and atherosclerosis 240 
[31-33]. In the presence of high glucose levels or insulin resistance, membrane CD36 241 
transcription and expression is upregulated and could lead to an almost 10-fold increase in 242 
CD36 mediated ox-LDL uptake [15, 29, 34], and thus may provide a mechanism for 243 
accelerated atherosclerosis in diabetic patients [29]. In addition, ox-LDL uptake by CD36 has 244 
shown to be dependent on the fatty acid that simultaneously binds to the same receptor [35]. 245 
Interestingly, recent studies have demonstrated that medications (peroxisome 246 
proliferator-activated receptor-gamma agonist and metformin), exercise and food extracts 247 
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(green tea polyphenols and cinnamon) could decrease CD36 expression in animal models and 248 
plasma levels in humans [34, 36-39]. Future studies should investigate whether such 249 
interventions might lower plasma CD36 among people with type 2 diabetes, and if lowering 250 
the plasma CD36 level translates into decreasing CHD-risk 251 
Given the previous associations particularly with ec olucent plaques, we propose that it 252 
would be worthwhile to expand the endpoint from pure CHD to all cardiovascular disease 253 
(such as including stroke events). Our current study only included CHD events and we cannot 254 
exclude that associations with stroke might be stronger.  255 
Our study has the strength of assessing the association between plasma CD36 and 256 
CHD risk, as well as exploring potential interactions with other CVD risk factors. In addition, 257 
the present study is a prospective design with large sample size; hence the recall bias in the 258 
exposure data prior to CHD diagnosis does not exist. However, some limitations merit 259 
consideration. First, we were only able to investigate the risk of CHD as we did not have 260 
plasma samples from stroke cases. Moreover, type 2 diabetes cases were self-reported in the 261 
current study and not identified by standardized blood testing, thus, underestimation of the 262 
type 2 diabetes may exist. In addition, we included relatively small number of diabetes cases 263 
and thus may have limited statistical power for the stratified analyses, however, our direction 264 
of association pointed towards the same direction compared to previous observations [18, 40, 265 
41]. Furthermore, we observed moderate batch variability, which was accounted for by 266 
batch-recalibration. However, even though this methodology can break any potential 267 
association between CD36 and potential confounders in the final Cox models, a smaller CV 268 
for the CD36 measurement would provide greater statistical power and precision in our 269 
analysis. As such, we cannot exclude that the largely null result in our study could be partly 270 
explained by our measurement error. Additionally, the present study was conducted among a 271 
Caucasian population living in Northern Europe, andthe results may not be applicable to 272 
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other ethnic groups. 273 
 274 
Conclusions 275 
In conclusion, we have observed that elevated plasma CD36 levels not associated 276 
with higher CHD risk in a general population. A tend cy for a higher risk was observed 277 
among participants with diabetes. Plasma (or circulating) CD36 concentration could be an 278 
interesting new marker that may link diabetes and atherosclerosis but future longitudinal 279 
studies are needed to examine the role of CD36 and risk of cardiovascular disease, 280 
particularly stroke, and to validate our findings in other ethnic groups. 281 
 282 
Conflict of interest 283 
 Dr. Handberg and the Ideas Clinic at Aalborg University Hospital hold two patents for the 284 
measurement of CD36 in plasma: "Method of evaluation of the relative risk of developing 285 
atherosclerosis in patients" 2006, WO2005/116644 and ”A method for diagnosing 286 
atherosclerotic plaques by measurement of CD36”, 2008,WO2008/ 095492.  287 
 288 
Financial support 289 
Genentech provided unrestricted funding for the measurement of plasma CD36 in the 290 
samples. The Diet, Cancer and Health Study was funded by the Danish Cancer Society.  291 
 292 
Author contributions 293 
 MKJ conceived the study, interpreted the data, and critically revised the reports. JZ analyzed 294 
and interpreted the data, and drafted the reports. YW drafted and critically revised the reports. 295 
AH measured the plasma samples of CD36 and critical revised the reports. KO, AT and EBR 296 
critically revised the reports. 297 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
 298 
Acknowledgements 299 
 We thank all the participants of the Danish Diet, Cancer and Health study. We also thank the 300 
technician Lone Larsen for dedicated measurements of CD36.  301 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
REFERENCES 302 
[1] C. Weber, H. Noels, Atherosclerosis: current pathogenesis and therapeutic options, Nat. 303 
Med. 17 (2011) 1410-1422. 304 
[2] S. Gautam, M. Banerjee, The macrophage Ox-LDL receptor, CD36 and its association 305 
with type II diabetes mellitus, Mol. Genet. Metab. 102 (2011) 389-398. 306 
[3] Y. Iwashima, M. Eto, A. Hata, et al., Advanced glycation end products-induced gene 307 
expression of scavenger receptors in cultured human onocyte-derived macrophages, 308 
Biochem. Biophys. Res. Commun. 277 (2000) 368-380. 309 
[4] J.M. Zingg, R. Ricciarelli, E. Andorno, et al., Novel 5' exon of scavenger receptor CD36 is 310 
expressed in cultured human vascular smooth muscle cells and atherosclerotic plaques, 311 
Arterioscler. Thromb. Vasc. Biol. 22 (2002) 412-417. 312 
[5] D.P. Koonen, R.L. Jacobs, M. Febbraio, et al., Increased hepatic CD36 expression 313 
contributes to dyslipidemia associated with diet-induced obesity, Diabetes. 56 (2007) 314 
2863-2871. 315 
[6] R.W. Schwenk, G.P. Holloway, J.J. Luiken, et al., Fatty acid transport across the cell 316 
membrane: regulation by fatty acid transporters, Prostaglandins. Leukot. Essent. Fatty Acids. 317 
82 (2010) 149-154. 318 
[7] X. Su, N.A. Abumrad, Cellular fatty acid uptake: a pathway under construction, Trends. 319 
Endocrinol. Metab. 20 (2009) 72-77. 320 
[8] J. Nigro, N. Osman, A.M. Dart, et al., Insulin resistance and atherosclerosis, Endocr. Rev. 321 
27 (2006) 242-259. 322 
[9] M. Febbraio, E.A. Podrez, J.D. Smith, et al., Targeted disruption of the class B scavenger 323 
receptor CD36 protects against atherosclerotic lesion development in mice, J. Clin. Invest. 105 324 
(2000) 1049-1056. 325 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
[10] M. Febbraio, E. Guy,R.L. Silverstein, Stem cell transplantation reveals that absence of 326 
macrophage CD36 is protective against atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 24 327 
(2004) 2333-2338. 328 
[11] R. Sherva, M.B. Miller, J.S. Pankow, et al., A whole-genome scan for stroke or 329 
myocardial infarction in family blood pressure program families, Stroke. 39 (2008) 1115-1120. 330 
[12] T.B. Dahl, A. Yndestad, M. Skjelland, et al., Increased expression of visfatin in 331 
macrophages of human unstable carotid and coronary atherosclerosis: possible role in 332 
inflammation and plaque destabilization, Circulation. 115 (2007) 972-980. 333 
[13] J.M. Zingg, R. Ricciarelli, A. Azzi, Scavenger receptor regulation and atherosclerosis, 334 
Biofactors. 11 (2000) 189-200. 335 
[14] M. Piechota, A. Banaszewska, J. Dudziak, et al., Highly upregulated expression of CD36 336 
and MSR1 in circulating monocytes of patients with acute coronary syndromes, Protein. J. 31 337 
(2012) 511-518. 338 
[15] M.J. Sampson, I.R. Davies, S. Braschi, et al., Increased expression of a scavenger receptor 339 
(CD36) in monocytes from subjects with Type 2 diabetes, Atherosclerosis. 167 (2003) 340 
129-134. 341 
[16] A. Bonen, M.L. Parolin, G.R. Steinberg, et al., Triacylglycerol accumulation in human 342 
obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid 343 
transport and increased sarcolemmal FAT/CD36, Faseb. J. 18 (2004) 1144-1146. 344 
[17] A. Bonen, N.N. Tandon, J.F. Glatz, et al., The fatty acid transporter FAT/CD36 is 345 
upregulated in subcutaneous and visceral adipose tis ues in human obesity and type 2 diabetes, 346 
Int. J. Obes. 30 (2006) 877-883. 347 
[18] A. Handberg, K. Levin, K. Hojlund, et al., Identification of the oxidized low-density 348 
lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance, 349 
Circulation. 114 (2006) 1169-1176. 350 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
[19] S. Heeboll, M.K. Poulsen, M.J. Ornstrup, et al., Circulating sCD36 levels in patients with 351 
non-alcoholic fatty liver disease and controls, Int. J. Obes. 41 (2017) 262-267. 352 
[20] A. Handberg, K. Hojlund, A. Gastaldelli, et al., Plasma sCD36 is associated with markers 353 
of atherosclerosis, insulin resistance and fatty liver n a nondiabetic healthy population, J. 354 
Intern. Med. 271 (2012) 294-304. 355 
[21] A. Handberg, M. Skjelland, A.E. Michelsen, et al., Soluble CD36 in plasma is increased in 356 
patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability, 357 
Stroke. 39 (2008) 3092-3095. 358 
[22] M. Rac, A. Krzystolik, M. Rac, et al., Is plasma-soluble CD36 associated with density of 359 
atheromatous plaque and ankle-brachial index in early-onset coronary artery disease patients?, 360 
Kardiol. Pol. 74 (2016) 570-575. 361 
[23] A. Tjonneland, A. Olsen, K. Boll, et al., Study esign, exposure variables, and 362 
socioeconomic determinants of participation in Diet, Cancer and Health: a population-based 363 
prospective cohort study of 57,053 men and women in De mark, Scand. J. Public Health. 35 364 
(2007) 432-441. 365 
[24] T.F. Andersen, M. Madsen, J. Jorgensen, et al., The Danish National Hospital Register. A 366 
valuable source of data for modern health sciences, Dan. Med. Bull. 46 (1999) 263-268. 367 
[25] C.B. Pedersen, H. Gotzsche, J.O. Moller, et al., The Danish Civil Registration System. A 368 
cohort of eight million persons, Dan. Med. Bull. 53 (2006) 441-449. 369 
[26] R.V. Luepker, F.S. Apple, R.H. Christenson, et al., Case definitions for acute coronary 370 
heart disease in epidemiology and clinical research studies: a statement from the AHA Council 371 
on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council 372 
on Epidemiology and Prevention; the European Society of Cardiology Working Group on 373 
Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National 374 
Heart, Lung, and Blood Institute, Circulation. 108 (2003) 2543-2549. 375 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
[27] A.M. Joensen, M.K. Jensen, K. Overvad, et al., Predictive values of acute coronary 376 
syndrome discharge diagnoses differed in the Danish National Patient Registry, J. Clin. 377 
Epidemiol. 62 (2009) 188-194. 378 
[28] B. Rosner, N. Cook, R. Portman, et al., Determination of blood pressure percentiles in 379 
normal-weight children: some methodological issues, Am. J. Epidemiol. 167 (2008) 653-666. 380 
[29] E. Griffin, A. Re, N. Hamel, et al., A link between diabetes and atherosclerosis: Glucose 381 
regulates expression of CD36 at the level of translation, Nat. Med. 7 (2001) 840-846. 382 
[30] C. Aguer, J. Mercier, C.Y. Man, et al., Intramyocellular lipid accumulation is associated 383 
with permanent relocation ex vivo and in vitro of fatty acid translocase (FAT)/CD36 in obese 384 
patients, Diabetologia. 53 (2010) 1151-1163. 385 
[31] J.F. Glatz, J.J. Luiken,A. Bonen, Membrane fatty cid transporters as regulators of lipid 386 
metabolism: implications for metabolic disease, Physiol. Rev. 90 (2010) 367-417. 387 
[32] D.P. Koonen, M.K. Jensen,A. Handberg, Soluble CD36- a marker of the 388 
(pathophysiological) role of CD36 in the metabolic syndrome?, Arch. Physiol. Biochem. 117 389 
(2011) 57-63. 390 
[33] M. Snel, J.T. Jonker, J. Schoones, et al., Ectopi  fat and insulin resistance: 391 
pathophysiology and effect of diet and lifestyle interventions, Int. J. Endocrinol. 2012 (2012) 392 
983814. 393 
[34] C.P. Liang, S. Han, H. Okamoto, et al., Increased CD36 protein as a response to defective 394 
insulin signaling in macrophages, J. Clin. Invest. 113 (2004) 764-773. 395 
[35] A.G. Jay, A.N. Chen, M.A. Paz, et al., CD36 binds oxidized low density lipoprotein 396 
(LDL) in a mechanism dependent upon fatty acid binding, J. Biol. Chem. 290 (2015) 397 
4590-4603. 398 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
[36] D. Glintborg, K. Hojlund, M. Andersen, et al., Soluble CD36 and risk markers of insulin 399 
resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly 400 
reduced during pioglitazone treatment, Diabetes Care. 31 (2008) 328-334. 401 
[37] A.C. Smith, K.L. Mullen, K.A. Junkin, et al., Metformin and exercise reduce muscle 402 
FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced 403 
hyperglycemia, Am. J. Physiol. Endocrinol. Metab. 293 (2007) E172-181. 404 
[38] B. Qin, M.M. Polansky, D. Harry, et al., Green tea polyphenols improve cardiac muscle 405 
mRNA and protein levels of signal pathways related to insulin and lipid metabolism and 406 
inflammation in insulin-resistant rats, Mol. Nutr. Food. Res. 54 Suppl 1 (2010) S14-23. 407 
[39] B. Qin, M.M. Polansky, R.A. Anderson, Cinnamon extract regulates plasma levels of 408 
adipose-derived factors and expression of multiple genes related to carbohydrate metabolism 409 
and lipogenesis in adipose tissue of fructose-fed rats, Horm. Metab. Res. 42 (2010) 187-193. 410 
[40] A. Handberg, A. Lopez-Bermejo, J. Bassols, et al., Circulating soluble CD36 is associated 411 
with glucose metabolism and interleukin-6 in glucose-intolerant men, Diab. Vasc. Dis. Res. 6 412 
(2009) 15-20. 413 
[41] R. Liani, B. Halvorsen, S. Sestili, et al., Plasma levels of soluble CD36, platelet activation, 414 
inflammation, and oxidative stress are increased in type 2 diabetic patients, Free. Radic. Biol. 415 
Med. 52 (2012) 1318-1324. 416 
417 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Table 1. Characteristics of participants who developed CHD during follow-up and sub-cohort 
members in the Diet, Cancer and Health study  
Variable Sub-cohort CHD cases 
N 1759 1963 
Age (yrs) 55.0 (50.0, 64.0) 58.0 (51.0, 64.0) 
Women  46.5% 27.2% 
    Postmenopausal (women)a 58.3%  71.0%  
    Current estrogen usea  31.7% 29.0%  
Education < 8 yrs, % (N) 33.5%  45.0%  
Current smoker, % (N) 37.8%  54.8%  
Alcohol, g/d 13.6 (0.7, 65.7) 13.6 (0.2, 69.2) 
Physical activity, METs/wk 60.00 (19.5, 155.0) 58.5 (16.5, 163.8) 
BMI (kg/m2) 25.6 (20.5, 33.0) 26.7 (21.1, 34.7) 
Diabetesb 1.8%  5.5%  
Hypertensionb 18.4%  31.3%  
Hypercholesterolemiab 8.0%  13.0%  
Plasma CD36, arbitrary units 0.62 (0.08, 2.67) 0.65 (0.08, 2.57) 
Median (5th and 95th percentiles) or %.   
aAmong women. 
bSelf-reported physician-diagnoses of diabetes, hypertension, and hypercholesterolemia. 
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Table 2. Least-squares means of plasma CD36 level in randomly selected participants from the 
Danish Diet, Cancer and Health Study. 
 Mean CD36 level (95% CI) pa 
Men 0.91 (0.85, 0.96)  
Women 0.82 (0.76, 0.88) 0.04 
Non smokers 0.90 (0.84, 0.95)  
Current smokers 0.81 (0.75, 0.88) 0.07 
Non-diabetes 0.87 (0.83, 0.91)  
Diabetes 0.71 (0.40, 1.03) 0.33 
Normal weight 0.82 (0.75, 0.88)  
Overweight 0.88 (0.82, 0.94) 0.18 
Obesity 0.97 (0.86, 1.08) 0.02 
Non hypercholesterolemia 0.86 (0.81, 0.90)  
Hypercholesterolemia 0.97 (0.82, 1.12) 0.16 
Data were means (95% CI), adjusted for age and sex (where appropriate). 
ap values for test of difference in means of CD36.   
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Table 3. Hazard Ratios (HRs) and 95% confidence intervals (95% CI) for coronary heart disease risk according to plasma CD36 level. 
  Tertiles of plasma CD36  Continuous 
  T1 T2 T3  Per SD (0.87 unit) p 
N cases/N at sub-cohort 595/586 676/588 692/585  
Median (interquartile range) 0.24 (0.12-0.33) 0.62 (0.52-0.73) 1.32 (1.03-2.04)  
Age and sex adjusted HR (95% CI) 1 (ref) 1.03 (0.87, 1.23) 1.03 (0.87, 1.22)  1.00 (0.93, 1.07) 0.89 
Multivariable model HRa (95% CI) 1 (ref) 1.00 (0.83, 1.21) 1.02 (0.84, 1.23)  1.01 (0.94, 1.09) 0.71 
HRs were obtained from Cox proportional hazard regression models stratified by sex.  
Tertiles created based on the distribution in the random sub-cohort. p-values were calculated using the continuous CD36 variables. 
aMultivariable model: adjusted for age, sex, BMI, smoking, alcohol, physical activity, education, self-reported hypercholesterolemia, and diabetes. 
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Table 4. Hazard ratios (HRs) and 95% confidence intervals for risk of coronary heart disease by joint categorization of CD36 tertiles and cardiovascular 
disease risk factors and continuous CD36 within strata. 
 Tertiles of plasma CD36  Continuous 
 T1 T2 T3  Per SD (0.87 unit) p 
Gender       
Female (N=1,336/N cases=534) 1 (ref) 1.08 (0.81, 1.43) 1.02 (0.76, 1.36)  0.98 (0.86, 1.13) 0.8 
Male (N=2,328/N cases=1,429) 2.76 (2.10, 3.64) 2.68 (2.07, 3.48) 2.80 (2.16, 3.62)  1.03 (0.94, 1.13) 0.5 
Current smoking status       
No smoking (N=1,961/N cases=888) 1 (ref) 1.01 (0.79, 1.28) 0.96 (0.76, 1.22)  0.99 (0.90, 1.09) 0.8 
Current smoking (N=1,703/N cases=1,075) 2.01 (1.54, 2.63) 2.02 (1.57, 2.60) 2.16 (1.66, 2.80)  1.04 (0.93, 1.16) 0.5 
Normal/Overweight/Obesity       
BMI <25 kg/m2 (N=1,362/N cases=603) 1 (ref) 1.15 (0.86, 1.55) 1.08 (0.80, 1.47)  1.03 (0.90, 1.18) 0.6 
BMI 25-30 kg/m2(N=1,638/N cases=923) 1.51 (1.13, 2.02) 1.47 (1.11, 1.95) 1.59 (1.19, 2.11)  1.01 (0.91, 1.11) 0.9 
BMI ≥30 kg/m2 (N=664/N cases=437) 2.71 (1.71, 4.30) 2.09 (1.45, 3.00) 1.97 (1.38, 2.82)  0.96 (0.79, 1.18) 0.7 
Diabetes       
No diabetes (N=3,530/N cases=1,855) 1 (ref) 1.00 (0.83, 1.21) 1.00 (0.83, 1.21)  1.01 (0.93, 1.08) 0.9 
Diabetes (N=134/N cases=108) 2.11 (0.87, 5.13) 1.99 (0.99, 3.99) 2.83 (1.08, 7.45)  1.37 (0.92, 2.04) 0.1 
Hypercholesterolemia       
No hypercholesterolemia (N=3,281 /N cases=1,707) 1 (ref) 1.06 (0.87, 1.30) 1.09 (0.89, 1.33)  1.01 (0.94, 1.09) 0.8 
Hypercholesterolemia (N=383/N cases=256) 2.41 (1.45, 3.98) 1.48 (0.96, 2.27) 1.49 (0.98, 2.26)  1.06 (0.80, 1.42) 0.7 
Models were adjusted for age, alcohol, physical activity, education; and for sex, smoking, BMI, self-reported hypercholesterolemia, and diabetes where 
appropriate.  
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• CD36 was not associated risk of coronary heart disease in the total population. 
• There was a suggestion of higher risk of coronary heart disease among participants 
with both high CD36 levels and existing diabetes.  
